Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 5, 2018

Boehringer and Domain Therapeutics form CNS drug discovery alliance

Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases.

Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases.

The multi-target project will focus on orphan G protein-coupled receptors (GPCRs), which are said to be one of the main therapeutic target classes. Though drugs targeting GPCRs constitute nearly 40% of all treatments on the market, only 15% of them are addressed.

The partners will leverage Domain’s DTect-All and bioSens-All platforms to identify new GPCR treatments for neuropsychiatric disorders.

Domain platforms are designed to characterise small molecule GPCR binders to screen as well as characterise potential lead compounds.

The company’s GPCR experts will also participate in the drug discovery project to support with knowledge and insights during the discovery phase.

Boehringer Ingelheim CNS Diseases Research global head Bernd Sommer said: “We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
“We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”

“We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”

The German pharmaceutical company will make an upfront payment to Domain, along with potential discovery, development and commercial milestones as well as royalties on sales.

Domain Therapeutics CEO Pascal Neuville said: “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets, and, coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”

The specific financial details of the deal have not been disclosed.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU